| Literature DB >> 33401551 |
Gaku Yamanaka1, Kanako Kanou1, Tomoko Takamatsu1, Mika Takeshita1, Shinichiro Morichi1, Shinji Suzuki1, Yu Ishida1, Yusuke Watanabe1, Soken Go1, Shingo Oana1, Hisashi Kawashima1.
Abstract
Complementary and integrative medicines (CIMs) are increasingly used as a preventive antimigraine therapy. In this review, we aimed to summarize the evidence for the efficacy and safety of eight CIMs (riboflavin, coenzyme Q10, magnesium, melatonin, polyunsaturated fatty acids, and combination therapy of feverfew, vitamin D, and ginkgolide B) in pediatric migraine prevention. The level of evidence for riboflavin was relatively high; it was investigated by many studies with five/seven studies demonstrating its efficacy. Five studies investigated the use of melatonin, with one reporting negative results. There was insufficient evidence on the effectiveness of coenzyme Q10, magnesium, and polyunsaturated fatty acids. Combination therapy showed positive potential; however, reports on the individual antimigraine effects of the CIMs were lacking. A definitive conclusion was not reached regarding the specific integrative drugs clinicians should choose for pediatric migraines, owing to low-quality evidence and a limited number of studies. Integrative medications are becoming more common for pediatric migraine prevention as they do not produce serious side effects, and underlying research data suggest their efficacy in preventing migraine. Additional studies are warranted to confirm the role of CIMs in treating patients with migraines.Entities:
Keywords: coenzyme Q10; feverfew; ginkgolide B; magnesium; melatonin; migraine; polyunsaturated fatty acids; riboflavin; vitamin D
Year: 2021 PMID: 33401551 PMCID: PMC7794736 DOI: 10.3390/jcm10010138
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241